Vyne Therapeutics Inc

Vyne Therapeutics Inc (NASDAQ: VYNE) is a pharmaceutical company. It focuses on developing proprietary and differentiated therapies in dermatology.

Investment Highlights – Watch at USD 1.53

• The Company made a loss from operations in Q2 FY2021.
• VYNE is dependent on external funding to run its operation.
• On the profitability front, the EBITDA margin in Q2 FY2021 has been lower than the industry median of 24.0%.
• On the liquidity front, the current ratio in Q2 FY2021 has been lower than the industry median of 2.73x.
• On the leverage front, the debt/equity ratio in Q2 FY2021 has been higher than the industry median of 0.42x.
• From a technical standpoint, the 20-day EMA at about USD 2.39 is sustaining above the stock price. Hence, there could be a correction in the stock price in the near term.

Recent Development 

New licensing: On 12 August 2021, the Company announced licensing of the BET inhibitor platform with In4Derm Ltd. Under this license, VYNE would get exclusive access to new chemical entities.

One Year Share Price Chart

(Source: Refinitiv, Analysis done by Kalkine Group)

Conclusion

Based on its loss-making operations, its dependence on external funding and the poorer profitability, liquidity and leverage position of the Company than the industry, we have given a "WATCH" stance on Vyne Therapeutics Inc at the closing market price of USD 1.53 (as of 18 August 2021).

*The reference data in this report has been partly sourced from Refinitiv.